/
Alnylam Pharmaceuticals, Inc. (also referred to as Alnylam, the Company, we, our or us) is a global commercial-stage biopharmaceutical company developing novel therapeutics based on ribonucleic acid interference, or RNAi. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression.
13.51% operating margin is respectable but not wide. ROIC at 28.69%. Suggests the business covers its cost of capital, but doesn't point to a wide moat.
Revenue up 65.2% YoY with margins expanding 21.4pp.
Insufficient data to identify specific risks. Treat any missing metrics as a data gap, not a clean bill of health.
Profitability & Returns
Revenue (TTM)
$3.71B
▲ +65.2% YoY
Net Income (TTM)
$314M
▲ +212.8% YoY
Op. Margin
13.51%
▲ +21.4pp YoY
ROIC
28.69%
▲ +40.1pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
$465M
▲ +1192.7% YoY
Op. Cash Flow (TTM)
$524M
▲ +6405.1% YoY
Net Debt
-$1.63B
Net Cash Position
Cash & Equiv.
$2.91B
5Y CAGR: +49.8%
Continue Research